Skip to main content
. 2023 Mar 28;41(15):2789–2799. doi: 10.1200/JCO.22.02558

FIG 1.

FIG 1.

Flow diagram for the STATICE Trial. aOne patient was excluded from the efficacy analysis by ICR owing to no measurable lesion. HER2, human epidermal growth factor receptor2; ICR, independent central review; IHC, immunohistochemistry; T-DXd, trastuzumab deruxtecan.